comparemela.com

Latest Breaking News On - Oncology research development at astrazeneca - Page 1 : comparemela.com

AstraZeneca notes positive trial results for Calquence treatment

AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma. Mantle.

United kingdomSusan galbraithGreg rosenvingeAlliance newsOncology research development at astrazenecaAlliance news ltdUnited kingdom basedOncology researchAll rights

Maintenance Osimertinib Demonstrates PFS Benefit in Stage III EGFR-Mutant NSCLC

Following chemoradiation, maintenance osimertinib improved PFS vs placebo in patients with stage III EGFR-mutant non–small cell lung cancer.

United statesSuresh ramalingamSusan galbraithWinship cancer institute of emory universityWorld health organizationOncology research development at astrazenecaWinship cancer instituteEmory universitySouth americaOncology researchEgfr mutant nsclcPhase 3 laura trial nct03521154

AstraZeneca and Daiichi Sankyo s Enhertu recommended for approval

AstraZeneca PLC and Daiichi Sankyo Co Ltd s Enhertu has been recommended for approval in the EU on Friday. Daiichi is a Tokyo-based pharmaceutical company. AstraZeneca is a Cambridge-based.

City ofUnited kingdomSophie roseDaiichi sankyoSusan galbraithDaiichi sankyo co ltd enhertuAlliance news ltdOncology research development at astrazenecaAlliance newsEuropean unionDaiichi sankyo co ltdOncology researchAll rights

Breast cancer drug found to work for many women, raising hope it may be extended to 16,800 NHS patients

Experts have identified a new subset of breast cancer patients who would benefit from the treatment

New yorkUnited statesUnited kingdomKotryna temcinaiteJane lowe meiselCharles swantonSusan galbraithNational institute for healthOncology research development at astrazenecaAmerican society of clinical oncologyCancer drugs fundCancer research united kingdomMemorial sloan kettering cancer centreAmerican societyClinical oncologyNorth america

vimarsana © 2020. All Rights Reserved.